Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Datasets
Search by expertise, name or affiliation
Prot#CB8025-21629: An 8-week, Dose Ranging, Open Label, Randomized, Phase 2 Study with a 44-Week Extension, to Evaluate the Safety and Efficacy of MBX-8025 in Subjects with Primary Biliary Cholangitis (PBC) and an Inadequate Response to or Intole
Flamm, Steven L
(PD/PI)
Medicine, Hepatology Division
Project
:
Research project
Overview
Project Details
Status
Finished
Effective start/end date
1/3/18
→
1/3/21
Funding
PRA Health Sciences
(CB8025-21629)
CymaBay Therapeutics, Inc.
(CB8025-21629)
View all
View less